BACKGROUND The 2014 Eighth Joint National Committee panel recommended a therapeutic target of systolic blood
I
n the United States, the number of individuals age $65 years is projected to nearly double to 84 million by 2050 (1) . The prevalence of hypertension is also expected to increase in parallel in this rapidly aging population, for whom cardiovascular disease remains the major cause of mortality and morbidity (2) Pressure Intervention Trial in older adults) in patients age $75 years has re-ignited the controversy of the optimal BP target in older hypertensive patients (6) .
The SPRINT-SENIOR trial evaluated a more aggressive strategy of a systolic BP target of <120 mm Hg versus a target of <140 mm Hg and showed a significant reduction of fatal and nonfatal major cardiovascular events and all-cause mortality, with no increase in serious adverse events with intensive treatment in patients age $75 years (6) . We aimed to assess the efficacy and safety of intensive BP-lowering strategies in older (age $65 years) hypertensive patients on the basis of the available evidence from all randomized controlled trials (RCTs).
METHODS
DATA SOURCES AND SEARCHES. We performed a systematic search, without language restriction, using the MEDLINE, Scopus, EMBASE, and Cochrane databases from 1965 to July 1, 2016, for RCTs comparing intensive BP lowering versus standard/ liberal BP lowering in older hypertensive patients.
Furthermore, we performed manual searches through the reference lists of studies, reviews, and pertinent meta-analyses. The search key words included the following MeSH terms: randomized controlled trial, target blood pressure, goal blood pressure, intensive blood pressure, tight blood pressure, elderly, and older patients (Online Table 1 ).
STUDY SELECTION. Studies were included if they met the following criteria: 1) RCTs comparing intensive versus standard or less intensive BP control; 2) including only older patients ($65 years) with hypertension; and 3) providing long-term data on cardiovascular and safety outcomes. Two physician reviewers (C.B. and S.B.) independently performed the data search, reviewed the originally identified titles and abstracts, and selected studies for pooled analysis on the basis of the inclusion criteria. Any divergence was resolved by consensus.
DATA EXTRACTION AND QUALITY ASSESSMENT. We extracted the following data from individual studies:
first author, year of publication, individual study inclusion and exclusion criteria, study and patient's characteristics, follow-up duration, and clinical outcomes in intensive and standard groups. Two investigators (C.B. and S.B.) independently assessed the study quality using Jadad criteria (7) as well as by the Cochrane collaboration's tool for assessing the bias in randomized trials (8) , focusing on the following domains: sequence generation, allocation concealment, blinding, outcomes assessment, and selective reporting.
STUDY OUTCOMES. We evaluated the following cardiovascular outcomes: 1) major adverse cardiovascular events (MACE); 2) cardiovascular mortality;
3) stroke; 4) myocardial infarction (MI); and 5) heart failure (HF). Safety outcomes of serious adverse events and renal failure were evaluated. The definition of MACE differed across studies, and the trial-specific definitions for each outcome were used.
DATA SYNTHESIS AND ANALYSIS. Statistical analysis was performed per recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic reviews and Meta-analyses guidelines (9,10) (Online Table 2 ). The analysis was performed on an intention-to-treat basis. Considering that the heterogeneity of the included trials might influence the treatment effect, we used a randomeffects model as the primary analysis to examine relative risks (RRs) and 95% confidence intervals (CIs) (11) . The results were confirmed by a fixed effects model to avoid small studies being overly weighted. Bavishi et al. The characteristics of patients in the included trials are shown in Table 2 . The SPRINT-SENIOR trial excluded patients with diabetes, and the proportion of patients with diabetes in the rest of the trials was low.
Assessment of reporting quality and risk of bias is presented in Online Table 4 . All studies were rated as high quality on the basis of the Jadad scale, and no evidence of high risk of bias was noted using the Table 5 ). Bavishi et al. Bavishi et al.
The greater use of diuretic agents in combination with angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in the intensive (vs. standard treatment) group of the SPRINT study, as compared to the other 3 studies, may have resulted in more pronounced alterations in intrarenal hemodynamics, leading to a rise in serum creatinine. This phenomenon is largely considered functional and reversible rather than a structural and irreversible rise in serum creatinine, in general, and is thought to be self-limited and nonprogressive (17) (18) (19) . However, in the SPRINT trial, the renal events were lower than expected, and the trial was terminated early. When interpreting the risks and benefits of intensive therapy, some numbers should be taken into The size of the square reflects the weight that the corresponding study contributes in the meta-analysis. The diamond represents the pooled risk ratio or the overall effect. Abbreviations as in Figure 1 .
JACC VOL. 69, NO. 5, 2017 Bavishi et al. Conversely, renal failure increased from 0.6% to 1.1%, or an absolute risk of 0.5% over the same time period.
Although one can argue that cardiovascular events and renal failure cannot be considered equivalent, clinicians and patients should be aware of the tradeoff involved with intensive therapy. Nevertheless in older patients, the cardiovascular benefit of intensive therapy may come at the expense of increase in adverse events. As shown in Table 2 , patients in the intensive treatment group used a higher number of antihypertensive medications, which was evident in all trials. The SPRINT-SENIOR (6) participants, on average, were taking more than 3 drugs every day in the intensive group. Also, the intensity of treatment may vary, and high medication dosages to achieve desired BP levels could substantially increase adverse effects. More importantly, older patients a have higher burden of comorbidities and are often exposed to polypharmacy (20) , which may further potentiate the risk of adverse events. Bavishi et al. Intensive Versus Standard BP Lowering in Older Hypertensive Patients
